এই পেইজের তথ্য মেডিকেল পরামর্শ হিসাবে বিবেচিত নয় এবং কোন চিকিৎসকের সাথে পরামর্শ করার বিকল্প হিসাবেও ব্যবহার করা যাবেনা ।
Phesgo® combines the same HER2+ breast cancer treatments as IV Perjeta® (pertuzumab) and Herceptin® (trastuzumab) into a single injection.1
The active substances in Phesgo, pertuzumab and trastuzumab, are monoclonal antibodies (a type of protein) that have been designed to attach to HER2. HER2 is a protein on cancer cells that makes the tumour cells grow more quickly and that is present in large quantities in about a quarter of breast cancers. By attaching to HER2, pertuzumab and trastuzumab stop HER2 from producing signals that cause the cancer cells to grow. They also activate cells of the immune system (the body’s natural defences), which then kill the cancer cells. Pertuzumab and trastuzumab attach to 2 different parts of HER2 and their actions have a complementary effect. These combined actions slow down cancer growth.2
Phesgo is given as an injection under the skin (Subcutaneous). The first dose is given over 8 minutes as an injection containing pertuzumab 1200 mg and trastuzumab 600 mg. This is followed by an injection containing pertuzumab 600 mg / trastuzumab 600 mg given over 5 minutes every 3 weeks. The duration of treatment depends on whether Phesgo is given before or after surgery, and on the type of breast cancer being treated.2
In Bangladesh Phesgo is approved for the following indications.3
Phesgo is indicated in combination with chemotherapy for the:
neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (see 3.1.2 Clinical Studies)
adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (see 3.1.2 Clinical Studies)
Phesgo is indicated in combination with docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Phesgo is available as
Vial 600 mg / 600 mg
Vial 1200 mg / 600 mg
Be sure to contact your doctor if you:
Are a woman who could become pregnant, or may be pregnant
If a patient becomes pregnant while receiving PHESGO, or within 7 months following the last dose of PHESGO, please immediately report pregnancy to the local Roche Adverse Event Line at
Additional information will be requested during a PHESGO-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of PHESGO and to provide appropriate information to health authorities, healthcare providers, and patients.
For additional information, please refer to the PHESGO prescribing information.
For additional information, please refer to
রোগীর সুরক্ষা এবং ঔষধের গুণগত মান নিশ্চিত করার জন্য, আমরা জোরালোভাবে পরামর্শ দিয়ে থাকি যে, কেনার আগে অবশ্যই ভালভাবে দেখে নেবেন যে প্রতিটি ঔষধে Roche Hologram Sticker, আছে কিনা এবং DGDA অনুমোদিত DAR (Drug Administration Registration) Number আছে কিনা। অন্য কোন উৎস থেকে প্রাপ্ত ঔষধ এর দায় রেডিয়েন্ট বা রোশ বাংলাদেশ এর কেউই গ্রহণ করবে না।
PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) | A Treatment for HER2-Positive Breast Cancer [Internet; cited 2024, January 28]. Retrieved from https://www.phesgo.com
Phesgo | European Medicines Agency [Internet; cited 2024, January 28]. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/phesgo
Phesgo Product Information BD Ro 7198574 December 2020